CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Cincinnati, Ohio, United States and 226 other locations
postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have diseas...
Phase 2
Cincinnati, Ohio, United States and 50 other locations
body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer...
Phase 2
Edgewood, Kentucky, United States and 9 other locations
for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previou...
Phase 3
Cincinnati, Ohio, United States of America and 40 other locations
how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast...
Phase 3
Montgomery, Ohio, United States and 118 other locations
with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determine...
Phase 2
Dayton, Ohio, United States of America and 42 other locations
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unre ...
Phase 3
Cincinnati, Ohio, United States and 163 other locations
of tumor and/or stromal area of infiltrating lymphocytes prior to initiation of standard neoadjuvant chemotherapy. At enrollment, patients ...
Phase 2
Edgewood, Kentucky, United States and 4 other locations
of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in...
Phase 3
Dayton, Ohio, United States and 173 other locations
ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2 ...
Phase 3
Cincinnati, Ohio, United States and 64 other locations
Clinical trials
Research sites
Resources
Legal